Italian patients, 105 (90.5%) had LOPD (symptom onset >12 months of age or ≤12 months without cardiomyopathy). Forty-nine out of 105 LOPD patients were enrolled over the time period from July 2010 to April 2013 in the Pompe Registry in Italy.
In group 1, the median ages of symptom onset and diagnosis in the Italian cohort of LOPD patients were 30 and 38 years, respectively. In group 2, the median age of symptom onset increased to 38 years, while the median age of diagnosis increased to 41 years. The average diagnostic gap (difference between age of symptom onset and age at diagnosis) has therefore decreased from 8 years to 3 years in this cohort of patients.
In group 2, the most common symptoms were proximal muscle weakness of the lower extremities (89%), trunk muscle weakness (75%), upper extremity muscle weakness (73%), and diffi cult ambulation (73%).
In group 2, 34% of patients required either non-invasive or invasive respiratory support compared with 25% of group 1.
In all, 68% of the group 2 patients were treated with enzyme replacement therapy with alglucosidase alfa compared with 54% in group 1. The median age of
